Our data suggest that JAM-A loss has a cell-autonomous, pro-tumorigenic effect of CRC progression that goes beyond the mere permissive effect of eliciting an inflammatory response due to impaired intestinal epithelium barrier function. The gene discussed is F11R; the disease is colorectal carcinoma.